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Validation of the Drug Abuse 
Screening Test (DAST-10): A study 
on illicit drug use among Chinese 
pregnant women
Lap Po Lam1, Wing Cheong Leung2, Patrick Ip3, Chun Bong Chow4, Mei Fung Chan1, 
Judy Wai Ying Ng1, Chu Sing2, Ying Hoo Lam5, Wing Lai Tony Mak5, Kam Ming Chow1 & 
Robert Kien Howe Chin2
We assessed the Chinese version of the Drug Abuse Screening Test (DAST-10) for identifying illicit 
drug use during pregnancy among Chinese population. Chinese pregnant women attending their first 
antenatal visit or their first unbooked visit to the maternity ward were recruited during a 4-month 
study period in 2011. The participants completed self-administered questionnaires on demographic 
information, a single question on illicit drug use during pregnancy and the DAST-10. Urine samples 
screened positive by the urine Point-of-Care Test were confirmed by gas chromatography-mass 
spectrometry. DAST-10 performance was compared with three different gold standards: urinalysis, 
self-reported drug use, and evidence of drug use by urinalysis or self-report. 1214 Chinese pregnant 
women participated in the study and 1085 complete DAST-10 forms were collected. Women who had 
used illicit drugs had significantly different DAST-10 scores than those who had not. The sensitivity of 
DAST-10 for identify illicit drug use in pregnant women ranged from 79.2% to 33.3% and specificity 
ranged from 67.7% to 99.7% using cut-off scores from ≥1 to ≥3. The ~80% sensitivity of DAST-10 
using a cut-off score of ≥1 should be sufficient for screening of illicit drug use in Chinese pregnant 
women, but validation tests for drug use are needed.
Illicit drug use during pregnancy causes significant adverse obstetric and fetal outcomes, and is becom-
ing an increasing major public health concern worldwide1–7. Early identification of illicit drug use by 
pregnant women during their antenatal visits would allow timely intervention to improve the perinatal 
outcomes8,9. Self-report measures are, by far, the most commonly used method of gathering information 
about drug use because they are cheap, easy to administer, and widely accessible10. The self-reported 
information could inform healthcare providers about the use of certain hazardous substances and 
can cover periods of drug use exceeding the detection window of urinary drug screening11. However, 
under-reporting of drug use may occur because respondents could fear possible negative social conse-
quences or being stigmatized12,13. Also, compulsory routine urine drug testing in clinical settings such 
as antenatal clinics may raise certain ethical issues14 and may not be cost effective. The Drug Abuse 
Screening Test (DAST) is a patient self-administered tool, which has been designed as a brief instru-
ment for clinical and non-clinical screening to detect potential drug abuse, which excludes alcohol and 
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tobacco, during the past 12 months15. However such self-reported screening measures were found to be 
lacking in Chinese populations.
In light of the alarming rise in illicit drug use in Chinese populations and lack of effective screening 
tools, we validated the Chinese version of Drug Abuse Screening Test (DAST-10) to detect illicit drug 
use among low risk Chinese pregnant women. We studied the psychometric properties of DAST-10 and 
examined its use in identifying illicit drug use during pregnancy and in assessing the degree of related 
problems.
Results
A total of 1483 Chinese pregnant women from Hong Kong were recruited during the 4-month study 
period, 1416 were attending their first antenatal visit and 67 were visiting the maternity ward for the first 
time. Overall, 1214 pregnant women participated in this study (81.9% response rate) and 1214 DAST-10 
(Chinese version) screening forms were collected. Demographic characteristics are shown in Table  1. 
Among the 1214 DAST-10 forms collected, 129 forms were not complete. Among the 1085 completed 
forms, the scores ranged from 0 to 8, with 66.6% scoring 0, 30.1% scoring 1, 2.2% scoring 2, and the 
Age 31.0
Gravidity 2 (1–3)
Parity - live birth 0 (0–1)
Number of previous terminations of pregnancy (TOPs) 0 (0–1)
On public financial assistance 2.4%
Single 7.9%
Unplanned pregnancy 23.5%
Smoking before pregnancy 15.7%
Smoking during pregnancy 1.4%
Drinking before pregnancy 4.1%
Drinking during pregnancy 0.1%
Illicit drug use before pregnancy 3%
Table 1.  Participant demographic characteristics (N = 1214). Age is presented as the mean, while 
gravidity, parity and number of TOPs are presented as the median and interquartile (25th–75th percentile) 
range.
Table 2.  Summary of the principal component analysis results for the DAST-10 (Chinese version) 
(N = 1085). aReverse score of Q3. Factor loadings over 0.40 are shaded.
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remaining scoring from 3 to 8. The median DAST score was 0 (interquartile range 0 to 1) among all the 
participants. The overall internal consistency was 0.64.
Among the 1085 women with completed DAST-10 forms, 3 urine samples were lost or spilt before 
transfer to laboratory for test. 13 urine samples were confirmed to be positive for one or more of the 
illicit drugs tested. Among the 1069 urine samples which screened negative by the POCT cards, 42 urine 
samples were randomly selected as negative controls for confirmatory GC-MS, which were all confirmed 
to be negative for any drugs.
In the anonymous questionnaires collected, one woman did not answer the single question on illicit 
drug use during current pregnancy, 14 women admitted to a history of illicit drug use during pregnancy 
and 1070 women denied a history of illicit drug use during pregnancy. A total of 24 pregnant women 
had either positive urinalysis for drug use or self-reported a history of illicit drug use.
Principal component analysis. A principal component analysis (PCA) was conducted on the 10 items 
of the DAST-10 using oblique rotation (direct oblimin). The Kaiser-Meyer-Olkin measure (KMO = 0.688) 
verified the sampling adequacy for the analysis. Barlett’s test of sphericity X 2 (45) = 1472.30 (P < 0.001) 
indicated the correlations between items were sufficiently large for PCA. Eigenvalues were calculated 
for each component in the data. Three components had eigenvalues over Kaiser’s criterion of 1 and in 
combination could explain 50.2% of the variance. Table 2 shows the factor loadings after rotation.
Criterion and concurrent validity. The DAST-10 scores of pregnant women were significantly dif-
ferent between those who had and those who had not used illicit drugs.
Using urinalysis as a measure of illicit drug use (Measure 1), 13 pregnant women had positive uri-
nalysis with a median DAST score of 1 (interquartile range 0 to 2), whereas 1069 women had negative 
urinalysis with a median DAST score of 0 (interquartile range 0 to 1; Mann–Whitney U test z = –3.39, 
P = 0.001). There was significant correlation between DAST-10 scores and the results of urinalysis 
(r = 0.103, P = 0.001, two tailed).
Using the self-reported single question as a measure of illicit drug use (Measure 2), 14 pregnant 
women self-reported illicit drug use during pregnancy with a median DAST score of 3 (interquartile 
range 1 to 5), whereas 1070 women reported no illicit drug use during pregnancy with a median DAST 
score of 0 (interquartile range 0 to 1; Mann–Whitney U test z = –6.64, P < 0.001). There was significant 
correlation between DAST-10 scores and the self-reported drug use (r = 0.202, P < 0.001, two tailed).
Using urinalysis-or-self-reported illicit drug use during pregnancy (Measure 3) as measure of illicit 
drug use, 24 pregnant women showed evidence of illicit drug use with a median DAST score of 2 (inter-
quartile range 1to 3), whereas 1061 women had no history of illicit drug use with a median DAST score 
of 0 (interquartile range 0 to 1; Mann–Whitney U test z = –6.31, P < 0.001). There was significant corre-
lation between DAST-10 scores and evidence of drug use by Measure 3 (r = 0.192, P < 0.001, two tailed).
The DAST-10 scores also significantly correlated with past history of illicit drug use before pregnancy 
(r = 0.141, P < 0.001, two tailed) and with current cigarette smoking (r = 0.061, P = 0.047, two tailed).
Face validity. The DAST-10 (Chinese version) had high face validity. Among the pregnant women 
with evidence of illicit drug use during pregnancy, those who denied current illicit drug use during 
Figure 1. Distribution of pregnant women admitting and denying current drug use (y axis) versus the 
total DAST-10 score (x-axis) for the detection of illicit drug use among pregnant women. 
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Figure 2. The ROC curve for DAST-10 detection of (a) positive urinalysis for illicit drug use 
(AUROC = 0.73; 95% CI, 0.56–0.89; asymptotic significance P = 0.005); (b) self-reported illicit drug use 
(AUROC = 0.93; 95% CI, 0.83–1.00; asymptotic significance P < 0.001); and (c) evidence of illicit drug use 
(AUROC = 0.81; 95% CI, 0.70–0.92; asymptotic significance P < 0.001).
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pregnancy had significantly lower DAST scores (Spearman’s rho correlation coefficient = – 0.67, P < 0.001, 
two-tailed) compared to those who admitted current illicit drug use. (Fig. 1)
Discriminative validity. Tables  3–5 show the corresponding sensitivity, specificity, positive predic-
tive value, negative predictive value and overall accuracy of the different DAST-10 cut-off scores. The 
AUROC was 0.73 for DAST-10 (95% CI, 0.56 to 0.89, asymptotic significance P = 0.005) detection of 
positive urinalysis for illicit drug use (Fig. 2a). The AUROC was 0.93 for DAST-10 (95% CI, 0.83 to 1.00, 
asymptotic significance P < 0.001) detection of self-reported illicit drug use during pregnancy (Fig. 2b). 
The AUROC was 0.81 for DAST-10 (95% CI, 0.70 to 0.92, asymptotic significance P < 0.001) detection 
of evidence of illicit drug use during pregnancy (Fig. 2c).
Degree of problems related to illicit drug use. The distribution of participants in the five cat-
egories of DAST-10 scores according to the degree of problems (0: No problem; 1–2 Low level; 3–5 
Moderate level; 6–8 Substantial level; 9–10 Severe level)16 are shown in Fig.  3. Among the pregnant 
women who used illicit drugs, the degree of problems shown by DAST-10 was significantly correlated 
with past history of illicit drug use before pregnancy (r = 0.458, P = 0.024, two tailed) and with a criminal 
history (r = 0.446, P = 0.033, two tailed), but there was no significant correlation with current cigarette 
smoking, alcohol drinking, gambling, domestic violence, psychiatric illness, sexually transmitted diseases 
or thrombosis.
Discussion
Illicit drug use is an important public health problem worldwide. In Hong Kong, a survey showed that 
1.6% of female students had history of illicit drug use17. For pregnant women, early identification of 
illicit drug use during their antenatal visits would allow timely intervention to improve the perinatal 
outcomes8,9. In clinical settings including antenatal clinics, compulsory use of routine urine drug test-
ing may raise certain ethical issues14 and may not be cost effective. Several instruments for substance 
abuse screening have been validated for use during pregnancy14. DAST-10 is a relatively brief tool for 
identifying potential drug-related problems15 and has been recommended as an assessment tool for use 
DAST cut-







≥ 1 69.2% 70.0% 2.4% 99.4% 67%
≥ 2 30.8% 97.1% 11.4% 99.1% 96.3%
≥ 3 23.0% 99.3% 27.3% 99.1% 98.3%
Table 3.  Sensitivity, specificity, positive predictive value, negative predictive values and overall accuracy 
of the different DAST-10 cut-off scores for detection of positive urinalysis (Measure 1).
DAST cut-







≥ 1 92.9% 67.4% 3.6% 99.9% 67.7%
≥ 2 78.6% 97.8% 31.4% 99.7% 97.5%
≥ 3 57.1% 99.7% 72.7% 99.4% 99.2%
Table 4.  Sensitivity, specificity, positive predictive value, negative predictive values and overall accuracy 
of the different DAST-10 cut-off scores for detection of self-reported illicit drug use during pregnancy 
(Measure 2).
DAST cut-







≥ 1 79.2% 67.7% 5.2% 99.3% 67.9%
≥ 2 50.0% 97.8% 34.3% 99.9% 96.8%
≥ 3 33.3% 99.7% 72.7% 98.5% 98.2%
Table 5.  Sensitivity, specificity, positive predictive value, negative predictive values and overall accuracy 
of the different DAST-10 cut-off scores for the detection of evidence of drug use by urinalysis or self-
report (Measure 3).
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Figure 3. Distribution of pregnant women with and without drug use (y axis) versus the five categories 
of DAST-10 scores (x axis) according to the degree of problems (0: No problem; 1–2 Low level; 3–5 
Moderate level; 6–8 Substantial level; 9–10 Severe level) for (a) urinalysis for illicit drug (Measure 1), (b) 
self-reported illicit drug use (Measure 2), and (c) evidence of drug use during pregnancy by urinalysis or 
self-report (Measure 3).
www.nature.com/scientificreports/
7Scientific RepoRts | 5:11420 | DOi: 10.1038/srep11420
in general medical settings18. One study showed that DAST-10 used in a primary care setting had 100% 
sensitivity (95% CI:90.6%–100%) and 77% specificity (95% CI: 71.5%–81.9%) using a cut-off ≥ 3 for the 
detection of problems related to current drug use19. Other studies showed a range of sensitivity (95% to 
41%) and specificity (42% to 99%) levels for different cut-off scores for DAST-10 used in the screening of 
psychiatric patients by structured interviews20–22. Our study on DAST-10 (Chinese version) also showed 
comparable results of a sensitivity of 92.9% and specificity of 67.4% for a cut-off score ≥ 1 when using 
self-reported drug use during pregnancy as the gold standard (Measure 2). The gold standards (criterion 
diagnosis) used in the above mentioned studies were self-reported structured interviews. It is possible 
that the respondent may deny drug use in the self-report question as well as in the DAST-10 screening. 
Hence, the validity of the screening in this situation may be falsely inflated23 by comparisons with gold 
standards based on such measures, resulting in high accuracy values in the above mentioned studies19–22. 
Furthermore, there was an inherent recall bias and report bias (mainly under-reporting) while filling in 
the DAST-10 screening form and answering the single question on illicit drug use.
Therefore, the use of bioanalytical measures as the gold standard for studying the validity of the screen-
ing tool would be more objective23. In our study, the use of urinalysis (Measure 1) could detect those 
pregnant women who did not report their current drug use and overcome the issue of under-reporting. 
And with the utilization of GC-MS, false positive results were eliminated. The sensitivity was 69.2% and 
specificity was 70.0% using a cut-off score ≥ 1, and was 30.8% and 97.1%, respectively, using cut-off score 
≥ 2. In the literature, a study on 274 high risk postpartum women (mainly low income African-American) 
examined the ability of DAST-10 to identify prenatal drug use using hair and urine samples as criterion 
variables10. The sensitivity was 47% and specificity was 82% using a cut-off score ≥ 1, and was 23% and 
94%, respectively, using cut-off score ≥ 2. Another study13 on 400 low-income, post-partum African 
American women showed an even lower sensitivity of 37% and specificity 83% using a cut-off score 
≥ 1, and sensitivity 7% and specificity 97% using a cut-off score ≥ 2. Due to the low sensitivity, it was 
suggested that the DAST-10 may have limited utility for pregnant women10.
However, using just either one of the methods (urinalysis or self-report drug use) as gold standards 
has limitations. In fact, the two methods are complementary to each other. Bioanalysis alone is not an 
ideal measure of illicit drug use. It may fail to detect drug use as it can only detect drug levels above a 
specific cut-off level within a specific period of time after drug use1. Negative results would be shown 
if the drug use is beyond the detection window (e.g. intermittent use)14, if the drug level in the sam-
ple is lower than the detection cut-off level, or if the drugs used are not included in the bioanalysis 
screening tests. The inclusion of self-report measure could, therefore, complement any limitations in the 
urinalysis, and is useful to detect the cases when illicit drug use is beyond detection by urinalysis. The 
evidence of drug use by urinalysis or self-report (Measure 3) detects drug use when EITHER urinalysis 
OR self-reported drug use is positive, as each method detects different types of pregnant women with 
illicit drug use of different patterns14,24. The results obtained by Measure 3 would be closer to the genuine 
situation than applying only one of the measures. Using Measure 3, the sensitivity was 79.2% using a 
cut-off score ≥ 1 and was 50% using a cut-off score ≥ 2, which was higher than using bioanalysis alone, 
and was also higher than reported by previous studies10,13.
Our study on DAST-10 (Chinese version) was performed on more than 1200 low risk pregnant women 
in a general antenatal clinic setting in a Chinese population, which was one of the largest study to date, 
compared to previous studies conducted on vulnerable populations (mainly low-income, postpartum 
women, African-American women)10,13. Furthermore, anonymity encouraged the pregnant women to 
Figure 4. A sample of the Drug Abuse Screening Test (DAST-10) Chinese Version. An English translation 
can be found in the Supplementary Information.
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participate and provide information without fear of being identified. The use of urinalysis was objective 
and could overcome the inherent bias of under-reporting, and the additional use of self-report question 
on drug use could complement the limitation of urinalysis, which was a strength in this validation study.
The internal consistency in our study was 0.64, which was low compared to other studies25. In studies 
on drug abuse screening of patients with psychiatric disorders, the coefficient alpha ranged from 0.86 
to 0.9420,22. In a study validating DAST-10 among African American pregnant women10 the coefficient 
alpha was 0.62, which was similar to the value obtained in our study, and is in the acceptable range for 
screening.
Among 1483 invited participants, total 1214 questionnaires were collected (response rate 81.9%). 
As participation was anonymous and volunteer, the data and background information of the 269 
non-participants was lacking. And because our study was anonymous in its design, test-retest reliabil-
ity could not be performed. The information of gestational age of women at the time of study was not 
included in the questionnaire, and the recall time period was not available for analysis. Nevertheless, the 
majority (99.9%) of the respondent were recruited from out-patient clinic at their first antenatal visits. 
In our antenatal clinic, around 70–80% of pregnant women were less than 20 weeks of gestation at their 
first antenatal visits. We also included the unbooked pregnant women attending the maternity ward for 
the first time because those with illicit drugs may have had no previous antenatal care5. As illicit drug use 
is illegal in Hong Kong, the participants were unlikely to recall incorrectly on their history of drug use 
while answering the single-question unless they deliberately denied such history. Our study showed that 
pregnant women who denied using illicit drugs during pregnancy tended to report lower DAST scores, 
which was also the case in a study by Skinner15. Because DAST has high face validity, it is susceptible to 
the respondents giving false answers to try to hide (drug-related) problems.
In light of the alarming rise in illicit drug use in Chinese populations and lack of effective screening 
tools, our study is the first to validate in the literature the Chinese version of DAST-10 to detect illicit 
drug use among low risk Chinese pregnant women. As it has not ever been applied to any other inde-
pendent groups (e.g. general population, men, non-pregnant women) of Chinese population, the com-
parison of our results with these groups is not possible. However the results in our study in assessing 
the DAST-10 (Chinese version) for identifying illicit drug use among Chinese pregnant women were 
comparable to the previous studies on validation of DAST-10 (English version) on detection of drug 
use among pregnant women in other population10,13,20–22. The Chinese version of the DAST-10 provides 
a viable option for clinicians to screen pregnant women for illicit drug use and to assess drug-related 
problems in Chinese populations. Using a cut-off score of ≥ 1, the sensitivity in our study approached 
80%, which could be sufficient for screening of illicit drug use in pregnancy among Chinese population, 
but further confirmatory measures are needed to confirm the status of drug use.
Methods
Drug Abuse Screening Test (DAST)-10. The DAST was developed and validated by Dr. Harvey A. 
Skinner at the Addiction Research Foundation, Toronto, Canada (now the Center for Addiction and 
Mental Health). The DAST is copyrighted by Dr. Harvey A. Skinner, although it has been made available 
for non-profit research, clinical, and training purposes. Permission for the use of DAST-10 in this study 
was obtained from the developer. The DAST-10 is a 10-item, yes/no, self-report instrument that has been 
shortened from the original 28-item DAST16. Each question answered with a “Yes” scores 1 point, except 
for Question 3, which scores 1 point for “No”. All items assess drug use in general, without referring to 
specific types of drugs. The words “drug use” and “drug abuse” used in the form refers to the use of any 
non-prescription drugs or the use of any prescribed or over-the-counter medications used in excess of 
the recommended doses. The questionnaire does not include any items on alcohol or tobacco.
Amphetamine 1000 ng/ml of d-amphetamine
Barbiturate 300 ng/ml of secobarbital
Benzodiazepine 300 ng/ml of oxazepam
Cocaine 300 ng/ml of benzoylecgonine
Ketamine 1000 ng/ml of ketamine
MDMA (Ecstasy) 500 ng/ml of MDMA
Methadone 300 ng/ml of methadone
Methamphetamine 1000 ng/ml of D-methamphetamine
Opiate 300 ng/ml of morphine
Cannabinoid/Marijuana 
(THC) 50 ng/ml of 11-nor-Δ 
9-THC-9-COOH
Table 6.  The cut-off concentrations for each drug used in the immunochemical assays.
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The Chinese version of the DAST-10 (Fig.  4) was first translated from English into Chinese by the 
first author and then back translated by an independent researcher with postgraduate qualifications 
(Supplementary Note S1). Both translators are bilingual. Variations between direct- and back-translations 
were discussed among authors and modified accordingly. The modified Chinese version was also sent to 
different obstetricians for comments before being used in the study. The Chinese version of the DAST-10 
questionnaire was made available to Chinese pregnant women attending the antenatal clinic, who could 
choose to complete the form anonymously. Information and instructions on the use of DAST-10 were 
given to the pregnant women before filling in the form.
Questionnaire. In the questionnaire, they were also asked directly whether they were currently using 
illicit drugs during their pregnancy, using the question “您在懷孕期間有濫用藥物嗎?” (translated into 
English as “Have you used any illicit drugs during your pregnancy?”).
Point-of-Care Testing (POCT) of Urine. The FirstSignTM One Step Multi Drug Screen (MDS-10) Cards 
and FirstSignTM One-Step Drug of Abuse Test Multi-drug (W.H.P.M., Inc.) were used to test the collected urine 
samples for the presence of the following drugs: Amphetamine (AMP), Barbiturate (BAR), Benzodiazepine 
(BZD), Cocaine (COC), Ketamine (KET), Methylenedioxymethamphetamine (MDMA/Ecstasy), 
Methadone (MTD), Methamphetamine (MAMP), Opiates (OPI), and Cannabinoids (THC). These drugs 
are the most commonly used drugs among adult drug users in Hong Kong26. The two assays are one-step 
lateral flow chromatographic immunoassays for qualitative determination of drug substances in human 
urine specimens based on the principle of competitive binding. Positive results are given if the urine 
contains any of the corresponding substances in amounts above the cut-off concentration. Table 6 shows 
the cut-off concentrations for each drug tested by the immunochemical assays27. These cut-off levels 
were deliberately selected to reflect significant exposure from substance use rather than accumulated 
environmental exposure.
Confirmatory test. The POCT immunoassay urine tests are sensitive28 but prone to cross reactiv-
ity27,29. The presence of commonly used medications, including chlorpheniramine and promethazine, 
could give rise false positives27. To ensure the quality of the study, validation tests were performed using 
Gas-chromatography-mass spectrometry (GC-MS) to confirm the presence of the drug. Urine sam-
ples screening negative by the POCT cards were randomly selected for GC-MS analysis as the negative 
controls.
Study population. The study was conducted in two major public hospitals (each with approximately 
5000 deliveries per year) in Hong Kong, Kwong Wah Hospital from May 2011 to June 2011 and Princess 
Margaret Hospital from September 2011 to October 2011. Local Chinese pregnant women newly attend-
ing the antenatal clinics and local unbooked Chinese pregnant women presenting to the maternity ward 
for the first time were recruited for the study. Pregnant women who were not Hong Kong residents were 
excluded from the study.
After routine urine testing for albumin and glucose, the pregnant women were asked to provide their 
urine samples. The urine sample, questionnaire with direct questions on illicit drug use during preg-
nancy, and the self-administered DAST-10 (Chinese version) screening form from the same pregnant 
woman were anonymously labeled with the same unique number. The DAST-10 scores were calculated 
from the DAST-10 screening forms. The urine samples collected were tested by POCT and were per-
formed by a trained staff who was blinded from the results of the DAST-10 screening and the results of 
the single question on self-reported drug use. Urine samples screened positive by the POCT were sent 
to a laboratory for confirmatory testing by gas chromatography-mass spectrometry. The laboratory staff 
performing the confirmatory tests was also blinded from the urine POCT results and all other results 
from DAST-10 or the self-report drug use.
Gold standards (Criterion diagnosis). Different measures were used as the gold standards for detec-
tion of illicit drug use and to assess the performance of DAST-10 in identifying illicit drug use during 
pregnancy. (Measure 1) Urinalysis: positive urinalysis results were urine samples that tested positive by 
the POCT assay confirmed by GC-MS, whereas negative urinalysis results were urine samples that tested 
negative by the POCT assay or tested negative by GC-MS. (Measure 2) Self-reported drug use: positive 
results were those pregnant women who self-reported illicit drug use during pregnancy, whereas negative 
results were those who reported no illicit drug use during pregnancy. (Measure 3) Evidence of drug use 
by urinalysis or self-report: positive results were those who were positive for either the urinalysis or the 
questionnaire result, whereas negative results were those who were negative for both the urinalysis and 
questionnaire result.
Details of the study were explained to the pregnant women by the nurses in the antenatal clinic or 
maternity ward, and the women were given an information sheet about the study. The pregnant women 
were free to choose whether to leave the urine sample or to fill in the anonymous questionnaires and 
DAST-10 screening form. Informed consent was obtained from all participants. Methods in the study 
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were carried out in accordance with the approved guidelines of the Clinical Research Ethics Committee 
of the Hong Kong Hospital Authority. Ethics approval was obtained from the Clinical Research Ethics 
Committee (Kowloon West Cluster) of the Hong Kong Hospital Authority.
Statistical analysis. Mann–Whitney U test was used to compare the difference of total DAST-10 
scores between participants with and without illicit drug use for each of the measures. Spearman’s rho 
correlation coefficients were obtained from bivariate correlation tests. Receiver Operating Characteristic 
(ROC) curve data, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) 
and overall accuracy with different cut-off scores of DAST-10 were calculated. Sensitivity refers to the 
true positive rate (i.e., the number of women scoring higher or equal to the cut-off score of DAST out of 
the number of those with positive results for illicit drug use). Specificity refers to the true negative rate 
(i.e., the number women scoring lower than the cut-off score out of the number of those with negative 
results for illicit drug use). PPV is defined as the proportion of true cases that were correctly identified 
by DAST-10 (the proportion of women scored higher or equal to the cut-off score of DAST having pos-
itive results for illicit drug). NPV is defined as the proportion of pregnant women with negative result 
for illicit drug use who were correctly identified by DAST-10 (the proportion of women scored lower 
than the cut-off score of DAST having negative results for illicit drug). Overall accuracy is defined as the 
number of true positives and true negatives among the total number of women undergoing the tests. For 
the ROC curves for DAST-10, test sensitivity vs. (1 – specificity) for each cut-off point was plotted. The 
area under the curve (AUROC) was calculated as a measure of overall test performance, with a score of 
1.0 representing a perfect test and a score of 0.5 a test that provided no information.
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